Comparison
5q14 3 Microdeletion Syndrome C4304529 vs 21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858
Clinical comparison between 5q14 3 Microdeletion Syndrome and 21 Hydroxylase Deficient Congenital Adrenal Hyperplasia for differential diagnosis and treatment planning.
5q14 3 Microdeletion Syndrome C4304529
A rare genetic condition involving deletion of a small region on chromosome 5, affecting brain development and often causing seizures and developmental issues.
21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858
An inherited disorder affecting adrenal hormone production, causing cortisol deficiency and other hormonal imbalances. Features may include ambiguous genitalia, salt-wasting crises, and growth issues. Treated with lifelong hormone replacement therapy.
6 comparison axes
Onset
5q14 3 Microdeletion Syndrome C4304529
Variable
21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858
0-null
Onset patterns differ
Severity
5q14 3 Microdeletion Syndrome C4304529
severe
21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858
severe
Different severity levels
Chronic
5q14 3 Microdeletion Syndrome C4304529
Chronic
21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858
Chronic
Differing course
Communicable
5q14 3 Microdeletion Syndrome C4304529
No
21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858
No
Different transmission
Body System
5q14 3 Microdeletion Syndrome C4304529
congenital
21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858
endocrine
Same/different system
Category
5q14 3 Microdeletion Syndrome C4304529
genetic
21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858
endocrine
Different category
Bottom line
5q14-3-microdeletion-syndrome-C4304529 and 21-hydroxylase-deficient-congenital-adrenal-hyperplasia-C2936858 differ in etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 5q14 3 Microdeletion Syndrome C4304529 | 21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858 | Discriminating power |
|---|---|---|---|
| Neurodevelopment | Developmental delay, hypotonia, or seizures may occur. | Primary features are hormonal rather than a brain-development deletion. | High |
| Adrenal or genital features | Ambiguous genitalia and salt-wasting are not established features. | Atypical genitalia, virilization, or salt-wasting crisis may occur. | High |
| Growth pattern | Growth effects are variable and not quantified here. | Androgen or cortisol imbalance may affect growth and puberty. | Moderate |
When to favor each condition
Choose 5q14 3 Microdeletion Syndrome C4304529 when
Developmental delay with seizures
This pattern better matches a neurodevelopmental microdeletion.
Moderate
Syndromic neurologic presentation
Genomic testing can assess a 5q14.3 deletion.
High
No adrenal crisis features
This does not exclude CAH, but favors further neurogenetic evaluation.
Low
Choose 21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858 when
Atypical genitalia or salt-wasting illness
An adrenal steroid disorder needs urgent consideration.
High
Cortisol deficiency or androgen excess
These endocrine features fit 21-hydroxylase deficiency better.
High
Family history suggesting CAH
Targeted biochemical and CYP21A2 testing is appropriate.
Moderate
How key tests differ
| Test | 5q14 3 Microdeletion Syndrome C4304529 | 21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858 | Interpretation |
|---|---|---|---|
| Chromosomal microarray | May detect a deletion involving 5q14.3. | No characteristic chromosomal deletion is expected. | A deletion supports the left condition but not adrenal disease. |
| Adrenal steroid profile | No characteristic abnormality is established. | 17-hydroxyprogesterone is often elevated; use laboratory reference ranges. | Abnormal steroids suggest CAH and require clinician confirmation. |
| CYP21A2 testing | Not the primary diagnostic test. | Pathogenic variants may confirm the enzyme disorder. | Interpret genetics together with clinical and biochemical findings. |
Prognosis comparison
5q14 3 Microdeletion Syndrome C4304529
- Outcome
- Often a chronic neurodevelopmental condition; exact prognosis is not established here.
- Factors
- Deletion extent, seizure control, and developmental support may influence outcome.
21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858
- Outcome
- A chronic endocrine disorder whose outcome varies with crisis prevention and hormone balance.
- Factors
- Salt-wasting status, adherence, and monitoring of growth and puberty are relevant.
Time frame: Both are generally lifelong; supplied CAH onset data are incomplete.
No prevalence or mortality should be inferred; clinician interpretation is required.
Complications comparison
| Complication | Presentation |
|---|---|
| Neurologic complications | Seizures and developmental disability may occur. Not a typical primary complication. Prominent neurologic disease points toward the microdeletion. |
| Adrenal crisis | Not expected from the supplied description. Salt-wasting crisis can be life-threatening. Suspected crisis requires urgent endocrine care. |
| Growth and reproductive effects | Specific long-term effects are not established here. Growth, puberty, fertility, or bone health may be affected. Endocrine monitoring is central for CAH. |
Patient education highlights
- HighDifferent causes
One is a chromosomal neurodevelopmental condition; the other is an inherited adrenal hormone disorder.
- HighUrgent symptoms
Seizures need prompt assessment. Vomiting, lethargy, dehydration, or shock in suspected CAH needs emergency care.
- MediumLong-term care
CAH commonly requires individualized hormone replacement; microdeletion care emphasizes development, seizures, and support.